

Report EurA1c 2025

HbA1c Trial
EQA organisers



I	Introduction and Overview of Results.....	2
II	Results EQA Fresh Whole Blood samples.....	5
III	Results EQA Lyophilised Hemolysate samples.....	11
IV	Value Assignment (Targeting).....	16
V	Homogeneity.....	16
VI	Stability.....	16
VII	Organisations and Persons involved.....	17

DRAFT Version,
15 July 2026
Carla Siebelder


I Introduction and Overview of Results

Introduction

26 EQA organisers of 21 countries agreed to participate in the 9th “EurA1c” project. The design is shown in figure 1.

15 EQA organisers used fresh whole blood samples and 15 organisers used lyophilised hemolysate samples (4 organisations used both fresh and lyophilised samples). In October 2025 the fresh whole blood samples were sent to the participants and immediately assayed. In November 2025 the lyophilised hemolysate samples were sent. These are assayed by the participants up to April 2026.

Figure 1. Design EurA1c Trial 2025



* In Germany, Italy and France 2 EQA organisers participated.

** In France 3 EQA organisers participated.

Confidentiality and Ownership

The results of the EurA1c project are owned by all EQA organisers. We agreed that reports are confidential and will not be shared with other third parties until the definite report is completed.

Time schedule EurA1c 2025:

April 2026	Interim report fresh whole blood 2025 and definite target values sent to all participating EQA organisers.
July 2026:	Draft full report sent to all who are involved in EurA1c 2025. At the same time the invitation to participate in EurA1c 2026 is sent.
31 August 2026:	Deadline for comments and remarks.
30 September 2026:	Final full report sent to all who are involved and published on the IFCC-HbA1c website (www.ifcchba1c.org). Results may be shared with third parties after publication on the IFCC-HbA1c website.

Value Assignment

Definite target values are assigned with the IFCC RMP.

For EurA1c 2025-1 the assigned value is 44.8 mmol/mol (expanded uncertainty 0.7 mmol/mol).

For EurA1c 2025-2 the assigned value is 58.1 mmol/mol (expanded uncertainty 0.9 mmol/mol).

Outliers

Participant outliers have been removed before calculation of the mean and between laboratory CV. Instead of using statistical criteria we only considered “blunders” as outliers. The criterion used was a difference exceeding 25% of the target values. In our opinion these results are a relevant picture of “real life”. In this way 18 results (0.6%) have been excluded from the database of the fresh whole blood samples and 16 results (1.2%) from the database of the lyophilised hemolysates.

Methods

Specification of the methods remains a point of consideration. Methods are described differently by the respective EQA organisers and also a significant number of labs did still do not report their manufacturer/method and/or their specific method. For details see resp. table 3/4 and 7/8.

Units

In some cases results were reported in NGSP units. We converted them to SI (IFCC) units using the Master Equation ($NGSP = 0.0915 IFCC + 2.15$) prior to calculation of means, SDs and making comparisons. All results in the report are in SI units.

Summary of Results

Table 1 summarizes the results. The participating EQA organisers are ranked per country in alphabetical order. Results are given for the fresh whole blood and lyophilised hemolysate samples.

Table 1. Results of EurA1c 2025

Country	EQA Organiser	Fresh Whole Blood			Lyophilised Hemolysate		
		n*	Mean Bias mmol/mol	Between Lab CV%	n*	Mean Bias mmol/mol	Between Lab CV%
Austria	ÖQUASTA				108	+1.2	4.7
Belgium	Sciensano	120	+1.3	3.2			
Czech Republic	SEKK	189	+1.3	4.1	160	+0.8	4.9
France	Asqualab	25	+0.8	2.9	22	+1.3	4.7
France	CTCB	145	+0.7	5.2	155	+0.9	3.3
France	ProBioQual	453	+1.2	3.2	423	+0.6	4.5
Germany	INSTAND	598	+0.4	4.3			
Germany	RfB	744	+0.8	3.8			
Greece	ESEAP				113	-0.4	6.6
International**	ERL				29	+0.3	2.9
Ireland	IEQAS	61	+0.1	3.3			
Italy	CRB	41	+1.2	4.4	34	+0.6	3.8
Italy	CRRVEQ	85	-0.1	5.7			
Korea	Kor Ass. EQAS				73	+0.2	2.4
Mexico	Grupo ERL-Mexico				23	+0.6	3.6
Netherlands	SKML	126	+0.7	3.6			
Portugal	PNAEQ				29	+1.3	6.5
South Africa	NHLS				6	+0.2	1.9
Spain	SEMEDLAB	140	+1.4	3.9			
Sweden	Equalis	110	+0.2	3.6			
Switzerland	CSCQ	50	+0.9	4.1			
Thailand	NIH				118	-0.9	9.8
Turkiye	TUBITAK UME				52	+0.2	5.5
United Kingdom	NEQAS	321	+1.3	3.5			
United Kingdom	Weqas	162	+0.8	4.2			
Vietnam	QCC				37	+2.9	4.0
Overall		3370	+0.8	4.0	1382	+0.5	5.4

* n = the number of datasets

** Individual laboratories of a number of countries

In total 4752 datasets were submitted for EurA1c 2025 (3370 in fresh whole blood and 1382 in lyophilised hemolysate).

The mean bias of all countries in the fresh whole blood programme is +0.8 mmol/mol and the between laboratory CV is 4.0%. In the lyophilised hemolysate programme the mean bias of all countries is +0.5 mmol/mol and the between laboratory CV is 5.4%.

Differentiation of Results

Results are differentiated per sample and a) per country b) per manufacturer/method and c) per manufacturer/method per EQA organiser in the fresh whole blood (section II) and in lyophilised hemolysates (section III) .

II Results EQA Fresh Whole Blood samples

Table 2 shows the results per EQA organiser for each sample. Tables 3 and 4 show the results per manufacturer/method for manufacturers/methods with 6 or more participants (table 3) and those with 5 or less participants (table 4).

Table 2. Results per EQA organiser for Fresh Whole Blood

Country	EQA Organiser	EurA1c 2025-1 Target 44.8 mmol/mol				EurA1c 2025-2 Target 58.1 mmol/mol				Mean 2 Samples	
		n	Mean	Bias	CV%	n	Mean	Bias	CV%	Bias	CV%
Belgium	Sciensano	120	45.7	+0.9	3.7	120	59.9	+1.8	2.8	+1.3	3.2
Czech Republic	SEKK	189	45.8	+1.0	4.1	189	59.7	+1.6	4.0	+1.3	4.1
France	Asqualab	25	45.3	+0.5	2.4	25	59.1	+1.0	3.3	+0.8	2.9
France	CTCB	143	45.6	+0.8	5.1	145	58.7	+0.6	5.2	+0.7	5.2
France	ProBioQual	448	45.9	+1.1	3.2	453	59.5	+1.4	3.1	+1.2	3.2
Germany	INSTAND	597	45.2	+0.4	4.4	598	58.5	+0.4	4.3	+0.4	4.3
Germany	RfB	744	45.5	+0.7	3.9	742	59.0	+0.9	3.7	+0.8	3.8
Ireland	IEQAS	61	45.0	+0.2	3.1	61	58.1	0.0	3.5	+0.1	3.3
Italy	CRB	40	46.0	+1.2	4.7	41	59.3	+1.2	4.2	+1.2	4.4
Italy	CRRVEQ	85	44.6	-0.2	6.2	85	58.1	0.0	5.2	-0.1	5.7
Netherlands	SKML	126	45.3	+0.5	3.6	126	59.0	+0.9	3.5	+0.7	3.6
Spain	SEMEDLAB	140	45.7	+0.9	4.0	140	59.9	+1.8	3.8	+1.4	3.9
Sweden	Equalis	110	44.9	+0.1	3.6	105	58.4	+0.3	3.6	+0.2	3.6
Switzerland	CSCQ	50	45.3	+0.5	3.7	49	59.4	+1.3	4.6	+0.9	4.1
United Kingdom	NEQAS	321	45.7	+0.9	3.6	321	59.8	+1.7	3.3	+1.3	3.5
United Kingdom	Weqas	162	45.4	+0.6	4.3	161	59.1	+1.0	4.1	+0.8	4.2
Overall		3361	45.5	+0.7	4.0	3361	59.1	+1.0	3.9	+0.8	4.0

Table 3. Results per Manufacturer/Method for Fresh Whole Blood (n>5)

Manufacturer/Method	EurA1c 2025-1 Target 44.8 mmol/mol				EurA1c 2025-2 Target 58.1 mmol/mol				Mean 2 Samples	
	n	Mean	Bias	CV%	n	Mean	Bias	CV%	Bias	CV%
Abbott Alinity	79	45.8	+1.0	2.6	80	58.6	+0.5	3.3	+0.8	2.9
Abbott ARCHITECT (enzymatic)	38	45.6	+0.8	3.3	38	58.8	+0.7	2.7	+0.8	3.0
Abbott/Alere Afinion	230	43.8	-1.0	4.2	224	57.1	-1.0	3.5	-1.0	3.9
Aidian QuickRead go HbA1c	9	44.0	-0.8	3.4	10	57.3	-0.8	7.5	-0.8	5.5
ARKRAY ADAMS HA-8180 series	129	45.6	+0.8	3.0	129	58.9	+0.8	3.0	+0.8	3.0
ARKRAY ADAMS HA-8190 series	73	45.5	+0.7	2.2	73	58.8	+0.7	1.9	+0.7	2.0
ARKRAY ADAMS HA-8380 series	7	46.1	+1.3	2.7	7	59.6	+1.5	2.5	+1.4	2.6
Beckman Coulter AU series	54	45.8	+1.0	3.6	54	58.1	0.0	2.9	+0.5	3.2
Bio-Rad D-10 series	104	45.6	+0.8	4.8	105	60.0	+1.9	4.7	+1.3	4.7
Bio-Rad D-100 series	143	43.8	-1.0	2.8	142	58.6	+0.5	2.2	-0.3	2.5
Bio-Rad Variant series	72	45.1	+0.3	3.5	72	59.8	+1.7	3.3	+1.0	3.4
Bio-Rad not specified/other	16	45.5	+0.7	2.2	16	60.3	+2.2	2.6	+1.5	2.4
Boditech AFIAS series	12	42.6	-2.2	10.1	12	57.0	-1.1	9.9	-1.6	10.0
EKF Diagnostics	26	45.0	+0.2	6.4	26	58.5	+0.4	5.0	+0.3	5.7
HemoCue HbA1c 501	14	44.4	-0.4	6.7	14	57.0	-1.1	7.3	-0.7	7.0
Menarini HbNEXT	30	47.0	+2.2	4.0	30	62.2	+4.1	3.9	+3.1	4.0
Ortho Clinical Diagnostics Vitros A1C1	11	48.1	+3.3	8.2	11	64.0	+5.9	8.1	+4.6	8.1
Roche Diagnostics cobas b 101	60	43.2	-1.6	4.8	59	56.1	-2.0	3.6	-1.8	4.2
Roche Diagnostics cobas c 111/311	6	44.3	-0.5	1.9	6	58.4	+0.3	1.9	-0.1	1.9
Roche Diagnostics cobas c 303/503	266	46.3	+1.5	3.3	267	58.4	+0.3	3.0	+0.9	3.2
Roche Diagnostics cobas c 501/502 (part of cobas 6000/8000)	163	46.1	+1.3	3.3	163	59.4	+1.3	3.7	+1.3	3.5
Roche Diagnostics cobas c 513	74	46.1	+1.3	2.6	74	58.5	+0.4	2.6	+0.8	2.6
Roche Diagnostics cobas Integra	41	45.4	+0.6	2.6	41	60.7	+2.6	3.0	+1.6	2.8
Roche Diagnostics not specified/other	35	45.4	+0.6	4.8	35	58.8	+0.7	4.1	+0.7	4.5
Sebia CAPILLARYS 2	46	45.7	+0.9	2.8	47	58.2	+0.1	2.7	+0.5	2.8
Sebia CAPILLARYS 3	356	45.6	+0.8	2.7	356	58.6	+0.5	2.0	+0.6	2.3
Sebia MINICAP	19	45.2	+0.4	3.1	20	57.9	-0.2	1.8	+0.1	2.5
Sebia not specified/other	6	44.7	-0.1	2.3	6	58.8	+0.7	1.3	+0.3	1.8
Siemens Atellica (enzymatic)	70	44.6	-0.2	3.7	70	57.3	-0.8	3.4	-0.5	3.6
Siemens DCA 2000/Vantage	182	45.2	+0.4	4.6	181	58.3	+0.2	4.5	+0.3	4.6
Siemens DCA Atellica	23	43.7	-1.1	3.6	23	56.6	-1.5	4.2	-1.3	3.9
Siemens Dimension EXL series	23	44.7	-0.1	3.6	24	57.4	-0.7	5.5	-0.4	4.5
Siemens not specified/other	22	44.5	-0.3	2.0	22	56.7	-1.5	2.5	-0.9	2.3
Tosoh G7	10	46.6	+1.8	2.8	10	61.2	+3.1	1.9	+2.5	2.4
Tosoh G8	181	46.1	+1.3	2.8	180	60.7	+2.6	2.2	+2.0	2.5
Tosoh G11	588	46.3	+1.5	2.3	590	61.0	+2.9	1.6	+2.2	1.9
Tosoh GR01	9	46.0	+1.2	1.5	9	61.6	+3.5	2.0	+2.3	1.8
Tosoh GX	17	46.2	+1.4	4.0	18	60.6	+2.5	4.2	+1.9	4.1
Tosoh not specified/other	18	46.2	+1.4	5.2	19	60.2	+2.1	4.7	+1.7	4.9
Trinity Biotech Premier Hb9210	27	46.9	+2.1	4.3	27	58.5	+0.4	3.5	+1.2	3.9
Not specified/other	41	44.1	-0.7	9.0	40	57.6	-0.5	6.3	-0.6	7.6

Table 4. Results per Manufacturer/Method for Fresh Whole Blood (n<6)

Manufacturer/Method	EurA1c 2025-1 Target 44.8 mmol/mol				EurA1c 2025-2 Target 58.1 mmol/mol				Mean 2 Samples	
	n	Mean	Bias	CV%	n	Mean	Bias	CV%	Bias	CV%
Abbott not specified/other	4	42.0	-2.8	7.0	4	54.8	-3.4	10.9	-3.1	9.0
ARKRAY ADAMS HA-8160 series	1	48.0	+3.2		1	62.0	+3.9		+3.6	
ARKRAY not specified/other	3	46.7	+1.9	6.5	3	60.3	+2.2	5.8	+2.1	6.2
Beckman Coulter Unicel DxC series	3	45.5	+0.7	1.1	3	58.2	+0.1	0.5	+0.4	0.8
Erba not specified/other	2	44.2	-0.6	1.9	2	56.7	-1.4	2.2	-1.0	2.0
Hitado	4	43.5	-1.3	11.5	4	60.1	+2.0	8.4	+0.3	10.0
Horiba Pentra	1	42.0	-2.8		1	57.9	-0.2		-1.5	
Lifotronic	1	44.4	-0.4		1	59.7	+1.6		+0.6	
Mindray not specified/other	1	46.1	+1.3		1	58.8	+0.7		+1.0	
Ortho Clinical Diagnostics Vitros FS	1	42.3	-2.5		1	52.6	-5.5		-4.0	
Randox RX series	1	44.7	-0.1		1	59.7	+1.6		+0.7	
Sysmex bx series	1	43.0	-1.8		1	57.0	-1.1		-1.5	
Sysmex not specified/other	2	42.6	-2.2	4.6	2	54.5	-3.6	6.5	-2.9	5.6
Thermo Fisher Scientific	1	46.0	+1.2		1	61.0	+2.9		+2.1	
Thermo Fisher Scientific/Konelab	5	46.7	+1.9	6.5	5	58.9	+0.8	6.4	+1.3	6.5

Table 5 shows the performance per manufacturer/method per EQA organiser. Included are only manufacturers/methods meeting 2 criteria: at least 6 participants per EQA organiser and at least two EQA organisers with at least 6 participants each. High biases (>2 mmol/mol) and high between laboratory CVs (>6%) are marked.

Table 5. Results per Manufacturer/Method and EQA organiser for Fresh Whole Blood (n>5)

Manufacturer/Method/EQA	n	EurA1c 2025-1 Target 44.8 mmol/mol		EurA1c 2025-2 Target 58.1 mmol/mol		Mean	
		Bias	CV%	Bias	CV%	Bias	CV%
Abbott Alinity							
Overall	79	+1.0	2.6	+0.5	3.3	+0.8	2.9
DE-INSTAND	14	+1.2	3.4	+0.9	3.4	+1.1	3.4
DE-RfB	17	+0.1	2.9	-0.4	2.9	-0.1	2.9
FR-ProBioQual	23	+1.5	1.0	+1.2	1.1	+1.3	1.1
SE-Equalis	9	+1.0	0.8	+0.5	1.8	+0.8	1.3
Abbott ARCHITECT (enzymatic)							
Overall	38	+0.8	3.3	+0.7	2.7	+0.8	3.0
DE-INSTAND	13	+0.2	4.5	+0.3	3.3	+0.2	3.9
DE-RfB	15	+1.3	1.1	+1.1	1.0	+1.2	1.0
Abbott/Alere Afinion							
Overall	230	-1.0	4.2	-1.0	3.5	-1.0	3.9
CH-CSCQ	10	-0.6	3.2	-1.0	2.3	-0.8	2.7
DE-INSTAND	67	-1.6	4.1	-1.6	4.1	-1.6	4.1
DE-RfB	28	-1.6	4.7	-1.7	3.7	-1.7	4.2
FR-Asqualab	7	+0.4	3.7	-0.5	2.6	-0.1	3.1
IE-IEQAS	14	-0.9	2.8	-0.9	2.6	-0.9	2.7
NL-SKML	19	-0.1	4.7	-0.3	3.8	-0.2	4.2
SE-Equalis	43	-0.4	4.3	-0.4	2.8	-0.4	3.6
UK-NEQAS	19	-1.0	2.9	-0.6	3.1	-0.8	3.0
UK-Wegas	17	-0.8	4.6	-0.4	2.9	-0.6	3.7
ARKRAY ADAMS HA-8180 series							
Overall	129	+0.8	3.0	+0.8	3.0	+0.8	3.0
BE-Sciensano	20	+0.8	2.5	+0.8	2.6	+0.8	2.5
CZ-SEKK	41	+0.8	3.9	+0.9	3.8	+0.8	3.8
DE-INSTAND	27	+0.9	2.1	+0.7	2.3	+0.8	2.2
DE-RfB	15	+0.9	2.5	+1.2	2.8	+1.1	2.6
NL-SKML	13	+0.4	3.0	+0.4	3.0	+0.4	3.0
ARKRAY ADAMS HA-8190 series							
Overall	73	+0.7	2.2	+0.7	1.9	+0.7	2.0
DE-RfB	6	+0.5	4.0	+0.5	3.4	+0.5	3.7
ES-SEMEDLAB	27	+0.6	2.0	+0.7	1.6	+0.6	1.8
IE-IEQAS	11	+0.9	1.4	+0.7	1.0	+0.8	1.2
UK-NEQAS	13	+1.1	1.9	+1.3	1.8	+1.2	1.8
UK-Wegas	8	+0.6	2.5	+0.3	1.6	+0.4	2.1
Beckman Coulter AU series							
Overall	54	+1.0	3.6	0.0	2.9	+0.5	3.2
DE-INSTAND	15	+0.3	2.8	-0.2	2.1	+0.1	2.4
DE-RfB	27	+1.1	3.4	+0.2	3.2	+0.7	3.3
Bio-Rad D-10 series							
Overall	104	+0.8	4.8	+1.9	4.7	+1.3	4.7
CZ-SEKK	23	+2.0	3.8	+3.0	3.0	+2.5	3.4
DE-INSTAND	22	+0.6	3.6	+2.2	4.0	+1.4	3.8
DE-RfB	24	+0.8	5.7	+2.1	4.5	+1.5	5.1
FR-CTCB	7	-2.4	6.1	-3.7	7.9	-3.0	7.0
FR-ProBioQual	17	+0.3	2.8	+1.8	2.1	+1.0	2.4
Bio-Rad D-100 series							
Overall	143	-1.0	2.8	+0.5	2.2	-0.3	2.5
BE-Sciensano	7	-0.8	3.9	+1.0	2.5	+0.1	3.2
DE-INSTAND	15	-0.5	3.1	+0.8	2.1	+0.1	2.6
DE-RfB	33	-1.3	2.4	+0.4	1.8	-0.4	2.1
ES-SEMEDLAB	18	-1.2	2.7	+0.4	2.4	-0.4	2.5
FR-ProBioQual	23	-0.5	2.6	+0.9	2.4	+0.2	2.5
UK-NEQAS	21	-0.9	2.3	+0.7	1.9	-0.1	2.1
UK-Wegas	6	-1.2	3.2	+0.2	1.6	-0.5	2.4

Manufacturer/Method/EQA	n	EurA1c 2025-1 Target 44.8 mmol/mol		EurA1c 2025-2 Target 58.1 mmol/mol		Mean	
		Bias	CV%	Bias	CV%	Bias	CV%
Bio-Rad Variant series							
Overall	72	+0.3	3.5	+1.7	3.3	+1.0	3.4
CZ-SEKK	8	-1.4	3.8	-0.7	2.4	-1.0	3.1
DE-INSTAND	10	+0.5	3.7	+2.7	3.6	+1.6	3.6
DE-RfB	20	+0.7	1.3	+2.3	1.1	+1.5	1.2
FR-ProBioQual	23	+0.8	3.5	+2.1	2.2	+1.5	2.9
Roche Diagnostics cobas b 101							
Overall	60	-1.6	4.8	-2.0	3.6	-1.8	4.2
IT-CRRVEQ	27	-1.6	5.1	-1.8	3.9	-1.7	4.5
UK-Wegas	10	-3.0	4.0	-3.7	1.8	-3.4	2.9
Roche Diagnostics cobas c 303/503							
Overall	266	+1.5	3.3	+0.3	3.0	+0.9	3.2
CH-CSCQ	10	+2.1	3.3	+1.0	2.3	+1.5	2.8
DE-INSTAND	87	+1.3	2.7	-0.1	2.6	+0.6	2.6
DE-RfB	107	+1.3	2.5	+0.3	2.6	+0.8	2.6
FR-ProBioQual	27	+1.9	3.3	+0.9	1.9	+1.4	2.6
NL-SKML	16	+0.9	3.1	+0.9	3.1	+0.9	3.1
Roche Diagnostics cobas c 501/502 (part of cobas 6000/8000)							
Overall	163	+1.3	3.3	+1.3	3.7	+1.3	3.5
DE-INSTAND	60	+1.4	2.5	+1.3	2.7	+1.4	2.6
DE-RfB	72	+1.4	3.7	+1.4	4.2	+1.4	3.9
IT-CRRVEQ	7	+1.2	3.3	+0.3	4.2	+0.8	3.8
NL-SKML	8	-0.1	4.9	+0.4	4.2	+0.1	4.5
Roche Diagnostics cobas c 513							
Overall	74	+1.3	2.6	+0.4	2.6	+0.8	2.6
DE-INSTAND	21	+1.5	2.8	+0.7	2.4	+1.1	2.6
DE-RfB	41	+1.0	2.3	+0.2	2.6	+0.6	2.4
Roche Diagnostics cobas Integra							
Overall	41	+0.6	2.6	+2.6	3.0	+1.6	2.8
DE-INSTAND	20	+0.5	2.3	+2.5	2.9	+1.5	2.6
DE-RfB	18	+0.7	3.1	+2.8	3.1	+1.8	3.1
Sebia CAPILLARYS 3							
Overall	356	+0.8	2.7	+0.5	2.0	+0.6	2.3
BE-Sciensano	19	+0.7	2.2	+1.0	1.8	+0.9	2.0
DE-INSTAND	15	+0.1	2.2	+0.2	1.9	+0.2	2.0
DE-RfB	47	+0.8	2.3	+0.6	2.1	+0.7	2.2
ES-SEMEDLAB	9	+0.6	1.8	-0.1	2.2	+0.3	2.0
FR-CTCB	66	+0.6	2.9	+0.3	1.6	+0.5	2.3
FR-ProBioQual	106	+0.9	2.3	+0.5	2.0	+0.7	2.1
IT-CRB	6	+1.4	3.2	+0.2	1.4	+0.8	2.3
IT-CRRVEQ	11	+0.5	4.9	+0.5	2.3	+0.5	3.6
NL-SKML	7	+1.0	2.5	+0.7	2.2	+0.8	2.3
SE-Equalis	17	-0.1	1.7	0.0	1.5	-0.1	1.6
UK-NEQAS	45	+1.4	3.0	+1.1	2.2	+1.3	2.6
Siemens Atellica (enzymatic)							
Overall	70	-0.2	3.7	-0.8	3.4	-0.5	3.6
DE-INSTAND	13	+0.1	3.1	-0.7	3.4	-0.3	3.2
DE-RfB	28	-0.2	4.3	-0.9	3.8	-0.5	4.0
FR-ProBioQual	8	+0.1	2.2	-1.5	2.6	-0.7	2.4
NL-SKML	6	-0.4	3.3	-0.2	2.4	-0.3	2.9
Siemens DCA 2000/Vantage							
Overall	182	+0.4	4.6	0.2	4.5	+0.3	4.6
DE-INSTAND	26	+0.1	5.5	-0.8	4.9	-0.3	5.2
DE-RfB	19	-0.1	4.8	-0.3	4.7	-0.2	4.7
FR-ProBioQual	20	+0.9	3.5	+0.6	4.1	+0.8	3.8
IE-IEQAS	20	+0.1	3.5	-0.4	4.0	-0.1	3.8
NL-SKML	9	+0.5	4.1	+1.6	6.7	+1.1	5.4
SE-Equalis	9	+0.9	3.9	+0.8	2.5	+0.8	3.2
UK-NEQAS	32	+0.5	6.2	+1.0	4.8	+0.7	5.5
UK-Wegas	40	+0.4	4.3	+0.2	4.1	+0.3	4.2

Manufacturer/Method/EQA	n	EurA1c 2025-1 Target 44.8 mmol/mol		EurA1c 2025-2 Target 58.1 mmol/mol		Mean	
		Bias	CV%	Bias	CV%	Bias	CV%
Siemens DCA Atellica							
Overall	23	-1.1	3.6	-1.5	4.2	-1.3	3.9
DE-RfB	7	-1.8	4.6	-2.9	5.2	-2.4	4.9
FR-ProBioQual	6	-0.3	3.5	-0.4	2.9	-0.4	3.2
UK-NEQAS	7	-1.4	2.9	-2.1	2.7	-1.7	2.8
Tosoh G8							
Overall	181	+1.3	2.8	+2.6	2.2	+2.0	2.5
BE-Sciensano	14	+0.8	2.0	+2.2	1.9	+1.5	1.9
CZ-SEKK	30	+2.2	2.5	+3.0	2.5	+2.6	2.5
DE-INSTAND	19	+1.1	2.3	+2.7	2.8	+1.9	2.5
DE-RfB	27	+1.1	1.6	+2.5	1.4	+1.8	1.5
ES-SEMEDLAB	7	+1.2	4.0	+2.0	1.4	+1.6	2.7
FR-CTCB	8	+2.5	4.0	+3.7	2.3	+3.1	3.1
FR-ProBioQual	39	+1.2	2.5	+2.5	1.9	+1.8	2.2
NL-SKML	14	+0.8	1.4	+1.9	1.1	+1.3	1.2
UK-NEQAS	7	+1.6	2.6	+3.0	1.8	+2.3	2.2
Tosoh G11							
Overall	588	+1.5	2.3	+2.9	1.6	+2.2	1.9
BE-Sciensano	38	+1.3	4.6	+2.8	0.8	+2.1	2.7
DE-INSTAND	38	+1.4	1.6	+2.8	1.4	+2.1	1.5
DE-RfB	124	+1.3	2.0	+2.7	1.4	+2.0	1.7
ES-SEMEDLAB	41	+1.6	2.0	+2.9	1.8	+2.3	1.9
FR-CTCB	18	+1.8	1.2	+3.0	1.0	+2.4	1.1
FR-ProBioQual	78	+1.6	2.6	+2.8	1.8	+2.2	2.2
IT-CRRVEQ	8	+1.1	3.2	+2.7	2.3	+1.9	2.7
NL-SKML	18	+1.3	1.9	+2.7	1.8	+2.0	1.8
SE-Equalis	12	+1.6	1.5	+3.2	1.2	+2.4	1.3
UK-NEQAS	138	+1.6	1.7	+2.9	1.4	+2.2	1.6
UK-Weqas	56	+1.6	1.7	+3.0	1.4	+2.3	1.5
Trinity Biotech Premier Hb9210							
Overall	27	+2.1	4.3	+0.4	3.5	+1.2	3.9
IT-CRB	9	+2.8	4.7	+1.5	3.3	+2.1	4.0
UK-NEQAS	6	+1.9	4.8	-0.8	3.1	+0.6	3.9
UK-Weqas	8	+1.8	4.8	-0.5	3.7	+0.7	4.3

III Results EQA Lyophilised Hemolysate samples

Table 6 shows the results per EQA organiser for each sample. Tables 7 and 8 show the results per manufacturer/method for those with 6 or more datasets (table 7) and 5 or less data sets (table 8).

Table 6. Results per EQA organiser for Lyophilised Hemolysate

Country	EQA Organiser	EurA1c 2025-1 Target 44.8 mmol/mol				EurA1c 2025-2 Target 58.1 mmol/mol				Mean 2 Samples	
		n	Mean	Bias	CV%	n	Mean	Bias	CV%	Bias	CV%
Austria	ÖQUASTA	108	46.4	+1.6	5.6	107	58.9	+0.8	3.8	+1.2	4.7
Czech Republic	SEKK	160	45.7	+0.9	4.9	160	58.7	+0.6	4.9	+0.8	4.9
France	Asqualab	22	46.2	+1.4	5.4	22	59.4	+1.3	4.1	+1.3	4.7
France	CTCB	155	45.9	+1.1	3.8	153	58.8	+0.7	2.7	+0.9	3.3
France	ProBioQual	422	45.7	+0.9	4.8	423	58.4	+0.3	4.2	+0.6	4.5
Greece	ESEAP	113	44.6	-0.2	7.3	109	57.4	-0.7	6.0	-0.4	6.6
International*	ERL	29	45.5	+0.7	3.5	28	57.9	-0.2	2.4	+0.3	2.9
Italy	CRB	34	45.3	+0.5	4.7	34	58.7	+0.6	2.8	+0.6	3.8
Korea	Kor Ass. EQAS	73	45.2	+0.4	2.6	73	58.2	+0.1	2.3	+0.2	2.4
Mexico	Grupo ERL-Mexico	23	45.7	+0.9	3.8	23	58.4	+0.3	3.5	+0.6	3.6
Portugal	PNAEQ	28	46.1	+1.3	7.0	29	59.3	+1.2	6.0	+1.3	6.5
South Africa	NHLS	6	44.7	-0.1	1.8	6	58.7	+0.6	2.1	+0.2	1.9
Thailand	NIH	113	44.1	-0.7	9.8	118	57.0	-1.1	9.9	-0.9	9.8
Turkiye	TUBITAK UME	52	45.3	+0.5	5.8	52	57.9	-0.2	5.2	+0.2	5.5
Vietnam	QCC	37	48.1	+3.3	3.9	37	60.5	+2.4	4.1	+2.9	4.0
Overall		1375	45.6	+0.8	5.7	1374	58.4	+0.3	5.1	+0.5	5.4

* Individual laboratories of a number of countries

Table 7. Results per Manufacturer/Method for Lyophilised Hemolysate (n>5)

Manufacturer/Method	EurA1c 2025-1 Target 44.8 mmol/mol				EurA1c 2025-2 Target 58.1 mmol/mol				Mean 2 Samples	
	n	Mean	Bias	CV%	n	Mean	Bias	CV%	Bias	CV%
Abbott Alinity	46	43.2	-1.6	6.1	45	55.4	-2.7	5.2	-2.1	5.6
Abbott ARCHITECT (enzymatic)	34	41.9	-2.9	9.5	33	54.7	-3.4	7.7	-3.1	8.6
ARKRAY ADAMS HA-8160 series	8	43.9	-0.9	2.3	8	55.6	-2.5	2.5	-1.7	2.4
ARKRAY ADAMS HA-8180 series	61	44.0	-0.8	3.8	61	55.9	-2.2	3.6	-1.5	3.7
ARKRAY ADAMS HA-8190 series	17	45.1	+0.3	1.5	17	57.1	-1.0	2.0	-0.4	1.8
ARKRAY ADAMS HA-8380 series	11	44.6	-0.2	6.1	11	56.7	-1.4	6.1	-0.8	6.1
Bio-Rad D-10 series	66	45.8	+1.0	5.4	64	60.0	+1.9	4.5	+1.4	4.9
Bio-Rad D-100 series	62	43.9	-0.9	2.1	62	57.8	-0.3	2.0	-0.6	2.1
Bio-Rad Variant series	37	44.2	-0.6	5.4	37	57.6	-0.5	4.7	-0.5	5.1
Lifotronic	21	44.1	-0.7	7.1	21	56.4	-1.7	5.2	-1.2	6.1
Menarini HbNEXT	27	43.7	-1.1	4.8	28	57.1	-1.0	3.8	-1.0	4.3
Mindray bs series	27	42.4	-2.4	9.6	27	54.4	-3.7	8.9	-3.0	9.3
Roche Diagnostics cobas c 111/311	17	47.4	+2.6	5.0	17	61.0	+2.9	3.2	+2.7	4.1
Roche Diagnostics cobas c 303/503	108	48.7	+3.9	4.4	110	60.7	+2.6	3.3	+3.2	3.8
Roche Diagnostics cobas c 501/502 (part of cobas 6000/8000)	64	47.5	+2.7	5.2	64	60.6	+2.5	4.6	+2.6	4.9
Roche Diagnostics cobas c 513	18	47.0	+2.2	2.8	18	59.2	+1.1	2.7	+1.7	2.7
Roche Diagnostics cobas Integra	13	46.9	+2.1	4.5	13	59.6	+1.5	4.0	+1.8	4.3
Roche Diagnostics not specified/other	25	47.2	+2.4	6.2	23	59.9	+1.8	3.8	+2.1	5.0
Sebia CAPILLARYS 2	11	45.8	+1.0	2.9	10	58.8	+0.7	1.8	+0.8	2.3
Sebia CAPILLARYS 3	216	45.7	+0.9	2.4	217	58.1	0.0	1.9	+0.4	2.1
Sebia MINICAP	10	45.0	+0.2	2.6	10	57.8	-0.3	2.4	-0.1	2.5
Sebia not specified/other	20	44.8	0.0	2.0	20	57.4	-0.7	2.3	-0.4	2.1
Siemens Atellica (enzymatic)	35	44.9	+0.1	6.0	34	56.6	-1.5	5.9	-0.7	6.0
Siemens DCA 2000/Vantage	18	50.4	+5.6	3.3	17	64.3	+6.2	2.8	+5.9	3.1
Siemens Dimension EXL series	6	46.6	+1.8	2.7	6	58.6	+0.5	3.8	+1.1	3.2
Tosoh G8	115	45.8	+1.0	3.2	113	58.9	+0.8	2.7	+0.9	3.0
Tosoh G11	175	45.7	+0.9	2.1	175	58.9	+0.8	3.0	+0.9	2.5
Tosoh GR01	12	46.1	+1.3	1.9	13	59.0	+0.9	1.6	+1.1	1.8
Tosoh GX	23	45.4	+0.6	3.7	24	58.4	+0.3	3.5	+0.4	3.6
Tosoh not specified/other	7	46.3	+1.5	2.2	7	59.9	+1.8	2.3	+1.7	2.2
Trinity Biotech Premier Hb9210	10	46.2	+1.4	6.4	10	58.6	+0.5	4.6	+1.0	5.5
Not specified/other	21	45.3	+0.5	8.5	25	58.0	-0.1	11.5	+0.2	10.0

Table 8. Results per Manufacturer/Method for Lyophilised Hemolysate ($n < 6$)

Manufacturer/Method	EurA1c 2025-1 Target 44.8 mmol/mol				EurA1c 2025-2 Target 58.1 mmol/mol				Mean 2 Samples	
	n	Mean	Bias	CV%	n	Mean	Bias	CV%	Bias	CV%
Abbott not specified/other	1	50.0	+5.2		1	62.0	+3.9		+4.6	
ARKRAY not specified/other	4	45.3	+0.5	3.3	4	57.3	-0.9	3.0	-0.2	3.1
Beckman Coulter AU series	5	50.9	+6.1	3.8	5	62.6	+4.5	3.0	+5.3	3.4
Beckman Coulter Unicel DxC series	2	47.0	+2.2	8.1	2	57.9	-0.2	9.3	+1.0	8.7
BioMajesty JCA-BM6010	3	41.9	-2.9	4.6	3	52.8	-5.3	6.8	-4.1	5.7
Bio-Rad not specified/other	3	46.0	+1.2	3.8	3	60.0	+1.9	3.3	+1.6	3.5
Erba not specified/other	1	45.3	+0.5		1	60.4	+2.3		+1.4	
Medconn MQ series	4	46.4	+1.6	4.9	3	59.1	+1.0	4.1	+1.3	4.5
Medicon Pictus/Medilyser series	4	41.1	-3.7	5.3	4	52.7	-5.4	6.4	-4.6	5.9
Ortho Clinical Diagnostics Vitros A1C1	1	43.2	-1.6							
Ortho Clinical Diagnostics Vitros FS					1	57.4	-0.7		-0.7	
Roche Diagnostics cobas b 101	3	37.0	-7.8	0.0	3	50.3	-7.8	4.6	-7.8	2.3
Siemens not specified/other	2	45.7	+0.9	7.3	2	58.7	+0.5	10.5	+0.7	8.9
Thermo Fisher Scientific	1	52.5	+7.7		2	65.6	+7.5	3.5	+7.6	3.5

Table 9 shows results per manufacturer/method per EQA organiser. Included are only manufacturers/methods meeting 2 criteria: at least 6 datasets per EQA organiser and at least two EQA organisers with at least 6 datasets each. High biases (>2 mmol/mol) and high between laboratory CVs (>6%) are marked.

Table 9. Results per Manufacturer/Method and EQA organiser for Lyophilised Hemolysate (n>5)

Manufacturer/Method/EQA	n	EurA1c 2025-1 Target 44.8 mmol/mol		EurA1c 2025-2 Target 58.1 mmol/mol		Mean 2 Samples	
		Bias	CV%	Bias	CV%	Bias	CV%
Abbott Alinity							
Overall	46	-1.6	6.1	-2.7	5.2	-2.1	5.6
FR-CTCB	10	+0.5	2.1	-0.4	1.3	+0.1	1.7
FR-ProBioQual	11	-0.8	1.7	-1.8	1.8	-1.3	1.8
GR-ESEAP	9	-2.2	3.7	-3.4	1.8	-2.8	2.7
TH-NIH	8	-6.3	4.1	-7.9	3.5	-7.1	3.8
Abbott ARCHITECT (enzymatic)							
Overall	34	-2.9	9.5	-3.4	7.7	-3.1	8.6
GR-ESEAP	15	-2.9	10.1	-2.4	6.8	-2.6	8.4
TH-NIH	8	-6.7	5.1	-8.6	3.4	-7.6	4.2
ARKRAY ADAMS HA-8180 series							
Overall	61	-0.8	3.8	-2.2	3.6	-1.5	3.7
AT-ÖQUASTA	14	+0.6	2.4	-0.4	2.6	+0.1	2.5
CZ-SEKK	36	-1.2	3.7	-2.9	3.1	-2.0	3.4
Bio-Rad D-10 series							
Overall	66	+1.0	5.4	+1.9	4.5	+1.4	4.9
CZ-SEKK	24	+2.1	5.3	+3.1	4.5	+2.6	4.9
FR-CTCB	6	+0.7	6.3	+1.6	2.9	+1.2	4.6
FR-ProBioQual	16	-0.6	3.3	+0.2	3.9	-0.2	3.6
Bio-Rad D-100 series							
Overall	62	-0.9	2.1	-0.3	2.0	-0.6	2.1
AT-ÖQUASTA	13	-0.9	2.0	-0.9	2.4	-0.9	2.2
FR-ProBioQual	12	-0.7	2.2	-0.5	2.1	-0.6	2.1
KR-Kor Ass. EQAS	18	-0.7	1.9	0.0	1.7	-0.4	1.8
Lifotronic							
Overall	21	-0.7	7.1	-1.7	5.2	-1.2	6.1
TH-NIH	6	-0.8	4.2	-2.7	2.5	-1.7	3.3
TR-TUBITAK UME	9	-1.3	5.2	-2.3	4.9	-1.8	5.0
Menarini HbNEXT							
Overall	27	-1.1	4.8	-1.0	3.8	-1.0	4.3
GR-ESEAP	15	-2.1	2.3	-2.3	1.7	-2.2	2.0
PT-PNAEQ	7	0.0	6.1	+0.6	4.0	+0.3	5.1
Roche Diagnostics cobas c 303/503							
Overall	108	+3.9	4.4	+2.6	3.3	+3.2	3.8
AT-ÖQUASTA	26	+4.4	3.5	+2.7	2.4	+3.6	2.9
FR-CTCB	5	+4.7	0.9	+2.8	2.9	+3.8	1.9
FR-ProBioQual	19	+5.3	4.5	+3.4	2.6	+4.3	3.6
GR-ESEAP	11	+3.5	3.5	+2.7	1.4	+3.1	2.4
TH-NIH	24	+3.0	3.5	+2.6	4.3	+2.8	3.9
VN-QCC	16	+3.1	4.0	+1.8	3.9	+2.5	4.0
Roche Diagnostics cobas c 501/502 (part of cobas 6000/8000)							
Overall	64	+2.7	5.2	+2.5	4.6	+2.6	4.9
AT-ÖQUASTA	15	+2.3	7.3	+1.8	3.6	+2.1	5.5
CZ-SEKK	6	+3.6	6.9	+3.0	6.7	+3.3	6.8
GR-ESEAP	7	+1.2	2.6	+1.8	3.2	+1.5	2.9
TH-NIH	12	+1.6	2.7	+2.1	6.3	+1.8	4.5
VN-QCC	16	+3.5	3.7	+3.0	4.6	+3.3	4.1
Sebia CAPILLARYS 3							
Overall	216	+0.9	2.4	0.0	1.9	+0.4	2.1
FR-CTCB	64	+1.1	1.7	+0.2	1.9	+0.7	1.8
FR-ProBioQual	125	+0.7	2.7	0.0	1.9	+0.4	2.3
INT-ERL*	8	+1.2	2.0	-0.2	1.4	+0.5	1.7
IT-CRB	6	+0.4	1.7	-0.1	1.1	+0.1	1.4

Manufacturer/Method/EQA	n	EurA1c 2025-1 Target 44.8 mmol/mol		EurA1c 2025-2 Target 58.1 mmol/mol		Mean 2 Samples	
		Bias	CV%	Bias	CV%	Bias	CV%
Tosoh G8							
Overall	115	+1.0	3.2	+0.8	2.7	+0.9	3.0
CZ-SEKK	37	+1.6	3.1	+1.6	2.6	+1.6	2.9
FR-CTCB	10	+0.4	0.9	+1.2	1.4	+0.8	1.1
FR-ProBioQual	37	+0.5	2.9	+0.2	2.5	+0.4	2.7
GR-ESEAP	9	+0.3	3.3	-0.6	2.4	-0.1	2.9
PT-PNAEQ	6	+1.0	2.9	+0.9	3.4	+1.0	3.1
Tosoh G11							
Overall	175	+0.9	2.1	+0.8	3.0	+0.9	2.5
AT-ÖQUASTA	9	+1.0	1.8	+0.8	2.0	+0.9	1.9
FR-CTCB	22	+1.0	1.4	+1.3	1.4	+1.2	1.4
FR-ProBioQual	84	+0.9	1.8	+0.5	3.1	+0.7	2.4
KR-Kor Ass. EQAS	32	+0.7	2.2	+0.4	2.0	+0.6	2.1
TR-TUBITAK UME	9	+0.7	1.8	+0.6	1.9	+0.7	1.8
Tosoh GX							
Overall	23	+0.6	3.7	+0.3	3.5	+0.4	3.6
FR-CTCB	5	+0.6	1.8	0.0	1.5	+0.3	1.6
FR-ProBioQual	8	+0.1	2.5	-0.4	2.4	-0.2	2.5

* Individual laboratories of a number of countries

IV. Value Assignment (Targeting)

The assigned values are the values as measured with the IFCC RMP in fresh whole blood. The samples have also been measured with the IFCC SRLs in the respective matrices. Table 12 shows the results; these values are for comparison and information.

Table 12. Results of Reference Measurement Procedures

Matrix	EurA1c 2025-1		EurA1c 2025-2	
	IFCC RMP mmol/mol	IFCC SRLs mmol/mol	IFCC RMP mmol/mol	IFCC SRLs mmol/mol
Fresh Whole Blood	44.8	45.8	58.1	58.9
Lyophilised Hemolysate		45.8		58.3
Frozen Whole Blood		45.1		58.6

V. Homogeneity

Homogeneity testing of EurA1c 2025-1 (fresh 2025-1 and lyophilised 2025-3) was performed according to ISO 13528:2022 Annex B with the ARKRAY HA-8190V (12 samples in duplicate). The samples may be considered to be adequately homogeneous if $s_s \leq 0.3 \text{ SD}_{PT}$. The results in table 13 show that the samples are homogeneous.

Table 13. Homogeneity test (HbA1c results in mmol/mol)

Vial	Fresh Whole Blood				Lyophilised Hemolysate			
	EurA1c 2025-1				EurA1c 2025-3			
	1	2	mean	Δ	1	2	mean	Δ
1	45.3	46.4	45.85	1.1	46,0	46,1	46,05	0,1
2	46.0	46.4	46.20	0.4	46,3	46,3	46,30	0,0
3	44.0	45.9	44.95	1.9	46,3	46,8	46,55	0,5
4	45.2	45.0	45.10	0.2	46,0	46,8	46,40	0,8
5	44.6	44.5	44.55	0.1	46,3	46,0	46,15	0,3
6	45.0	44.6	44.80	0.4	46,1	46,7	46,40	0,6
7	45.3	45.6	45.45	0.3	46,4	46,0	46,20	0,4
8	45.9	44.5	45.20	1.4	46,4	46,3	46,35	0,1
9	45.0	45.9	45.45	0.9	46,3	46,4	46,35	0,1
10	45.0	44.3	44.65	0.7	46,0	46,1	46,05	0,1
11	44.6	44.9	44.75	0.3	46,1	46,0	46,05	0,1
12	46.3	46.0	46.15	0.3	46,1	46,1	46,10	0,0
average			45.3				46.2	
SD		0.378	0.570	0.603		0.000	0.168	0.254
S_s			0.406				0.415	
Criterion ($0.3 \times \text{SD}_{PT}$)			-0.029				-0.415	
Homogeneity:			Pass				Pass	

VI. Stability

Stability studies of the fresh whole blood and lyophilised hemolysate samples were completed. Results show that Fresh Whole Blood samples are stable for 5 days at room temperature and for at least 8 days in the refrigerator. Lyophilised Hemolysate samples are stable for five years when stored in the freezer at -20°C or lower.

VII. Organisations and Persons Involved

Country	Organisation	Person
EQA Organisers		
AT	ÖQUASTA	Christoph Buchta
BE	Sciensano	Yolande Lenga
CH	CSCQ	Pierre-Alain Morandi, Dagmar Kessler
CZ	SEKK	Marek Budina, Josef Kratochvila, Ondrej Wiewiorka
DE	INSTAND	Patricia Kaiser
DE	Reference Institute for Bioanalytics	Anja Kessler
ES	SEMEDLAB)	Sandra Bullich, Montserrat Ventura, Mariona Panadès, Berta Piqueras, Sandra Bullich
FR	Asqualab	Anne Vassault.
FR	CTCB	Stéphanie Albarède, Safouane Hamdi
FR	ProBioQual	Philippe Joly, Bernard Poggi
GR	ESEAP/General Hospital	Alexander Haliassos, Konstantinos Makris, Otto Panagiotakis
IE	IEQAS	Anne Kane, Hazel Graham, Marguerite MacMahon, Phyllis Reilly
INT	ERL	Carla Siebelder, Rogier Schoeman
IT	Centro di Ricerca Biomedica	Laura Sciacovelli, Mario Plebani
IT	CRRVEQ	Massimo Quercioli, Paola Pezzati, Francesca Masi
KR	Korean Association of External Quality Assessment Service	Junghan Song, Sail Chun, Kyunghoon Lee
MX	Laboratorios Biomedicos Panuco	Eduardo Rojano Rodriguez
NL	SKML	Hans van der Vuurst
PT	PNAEQ-INSA	Ana Paula Faria, Helena Correia
SE	Equalis	Jim Andersson, Hanna Börjeson
TH	National Institute of Health	Supaporn Suparak
TR	TUBITAK UME / Pamukkale University	Diler Aslan, Gonca Altin
UK	UK NEQAS	Rachel Marrington, Finlay MacKenzie
UK	Wegas	Annette Thomas, Samantha Jones, Gareth Davies
VN	Quality Control Center for Medical Laboratory- Hanoi Medical University	Le Vu Huyen Trang
ZA	NHLS/Stellenbosch University	Annalise Zemlin
IFCC Network Laboratories		
FR	CHU Reims	Stéphane Jaisson
DE	INSTAND	Patricia Kaiser
DE	Reference Institute for Bioanalytics, Calibration Laboratory 1	Caroline Stobe, Birgit Zinndorf
NL	Isala	Erna Lenters-Westra, Robbert Slingerland, Janine Slootstra
NL	Queen Beatrix Hospital	Carla Siebelder, Sanne Leppink, Laura Reijnders, Rogier Schoeman
IFCC Secondary Reference Laboratories		
IT	CIRME	Renata Paleari
NL	Isala	Erna Lenters, Robbert Slingerland
NL	Queen Beatrix Hospital	Carla Siebelder, Sanne Leppink, Laura Reijnders Rogier Schoeman
Oversight Committee (members IFCC C-EUBD)		
UK	University of Cambridge	Emma English
CZ	University of Prague	Jan Skrha
UK	Manchester University	Eric Kilpatrick
US	Abbott Chicago	Liza Kunz
KR	Seoul National University Bundang Hospital	Kyunghoon Lee
US	National Institutes of Health	David B. Sacks
NL	Queen Beatrix Hospital	Carla Siebelder
NL	Isala	Erna Lenters
ZA	NHLS Cape Town	Annalise Zemlin
Trial Management (European Reference Laboratory, Queen Beatrix Hospital)		
NL	Overview	Carla Siebelder
NL	Coordination	Carla Siebelder
NL	Quality Assurance	Liesbeth Janssen
NL	Data Processing	Irene de Graaf
NL	Sample Logistics	Marieke te Winkel